公开(公告)号：WO1995020664A2

公开(公告)日：1995-08-03

申请号：PCT/US1995001087

申请日：1995-01-27

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  WATANABE, Shinichi ,  YAMAGUCHI, Julie ,  DESAI, Suresh, M. ,  DEVARE, Sushil, G.

IPC: C12N15/57

CPC classification number: C07K14/005 ,  A61K39/00 ,  C07K14/4711 ,  C07K2319/00 ,  C12N2770/24222 ,  Y10S436/82

Abstract: Mammalian expression systems for the production of HCV E1-E2 fusion proteins. Such expression systems provide high yields of HCV proteins extracellularly, and enable the development of diagnostic, vaccine and therapeutic reagents which contain glycosylated structural antigens and also allow for the isolation of the HCV etiological agent.

Abstract translation: 用于生产HCV E1-E2融合蛋白的哺乳动物表达系统。 这种表达系统在细胞外提供高产量的HCV蛋白质，并且能够开发含有糖基化结构抗原的诊断，疫苗和治疗试剂，并且还允许HCV病原体的分离。

公开(公告)号：EP0741787B1

公开(公告)日：2003-07-09

申请号：EP95908700.8

申请日：1995-01-27

Applicant: Abbott Laboratories

Inventor： WATANABE, Shinichi ,  YAMAGUCHI, Julie ,  DESAI, Suresh, M. ,  DEVARE, Sushil, G.

IPC: C12N15/57 ,  C12N15/62 ,  G01N33/576

CPC classification number: C07K14/005 ,  A61K39/00 ,  C07K14/4711 ,  C07K2319/00 ,  C12N2770/24222 ,  Y10S436/82

Abstract: Mammalian expression systems for the production of HCV E1-E2 fusion proteins. Such expression systems provide high yields of HCV proteins extracellularly, and enable the development of diagnostic, vaccine and therapeutic reagents which contain glycosylated structural antigens and also allow for the isolation of the HCV etiological agent.

公开(公告)号：EP0741787A1

公开(公告)日：1996-11-13

申请号：EP95908700.0

申请日：1995-01-27

Applicant: Abbott Laboratories

Inventor： WATANABE, Shinichi ,  YAMAGUCHI, Julie ,  DESAI, Suresh, M. ,  DEVARE, Sushil, G.

IPC: G01N33 ,  A61K39 ,  A61P31 ,  C07H21 ,  C07K14 ,  C07K16 ,  C07K19 ,  C12N15 ,  C12P21

CPC classification number: C07K14/005 ,  A61K39/00 ,  C07K14/4711 ,  C07K2319/00 ,  C12N2770/24222 ,  Y10S436/82

Abstract: Mammalian expression systems for the production of HCV E1-E2 fusion proteins. Such expression systems provide high yields of HCV proteins extracellularly, and enable the development of diagnostic, vaccine and therapeutic reagents which contain glycosylated structural antigens and also allow for the isolation of the HCV etiological agent.